HEALTH CARE
Shares of Eli Lilly and Co. rose as much as 4.6 percent on Feb. 19 after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large Phase 3 trial. When ramucirumab was applied to non-small-cell lung cancer, along with a traditional chemotherapy drug, it showed a statistically […]